Aratana Therapeutics, Inc. (PETX) financial statements (2022 and earlier)

Company profile

Business Address 11400 TOMAHAWK CREEK PARKWAY, SUITE 340
LEAWOOD, KS 66211
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments42,67167,61588,30386,20298,07245,754
Cash and cash equivalents41,43166,86887,30726,7559,82341,084
Short-term investments1,24074799659,44788,2494,670
Receivables2,2042,4068760352 
Inventory, net of allowances, customer advances and progress billings11,42513,57611,1301,30642755
Inventory11,42513,57611,1301,30642755
Deferred costs 7620189  
Other undisclosed current assets1,8271,5662,0021,2621,0582,656
Total current assets:58,12785,239101,54289,01999,90948,465
Noncurrent Assets
Property, plant and equipment6931,1661,9482,55562098
Long-term investments and receivables    2,452 
Long-term investments    2,452 
Intangible assets, net (including goodwill)46,94547,91147,02154,848103,72166,936
Goodwill40,84641,29539,38239,78141,39820,796
Intangible assets, net (excluding goodwill)6,0996,6167,63915,06762,32346,140
Restricted cash and investments351350350350  
Other noncurrent assets3205265452941,20137
Total noncurrent assets:48,30949,95349,86458,047107,99467,071
TOTAL ASSETS:106,436135,192151,406147,066207,903115,536
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,41211,16313,2635,6476,8195,819
Accounts payable9117,4517,4361,4001,5322,307
Accrued liabilities1,9143,7125,8274,2473,2292,495
Employee-related liabilities2,587   2,0171,017
Interest and dividends payable    41 
Debt 17,33314,413  8,625
Business combination, contingent consideration, liability    4,248
Deferred revenue and credits    800
Deferred tax liabilities    413 
Other liabilities  12374657
Other undisclosed current liabilities1457,0007,000 (2,058)1,600
Total current liabilities:5,55735,49634,6885,6849,46816,901
Noncurrent Liabilities
Long-term debt and lease obligation 19,49225,77539,71014,9639,310
Long-term debt, excluding current maturities 19,49225,77539,71014,9639,310
Liabilities, other than long-term debt57705401221,6401,741
Deferred tax liabilities, net    1,6101,666
Other liabilities57705401223075
Other undisclosed noncurrent liabilities     1,543
Total noncurrent liabilities:5719,56226,31539,83216,60312,594
Total liabilities:5,61455,05861,00345,51626,07129,495
Stockholders' equity
Stockholders' equity attributable to parent, including:100,82280,13490,403101,550181,83286,041
Common stock484337353423
Treasury stock, value(1,175)(1,107)(1,088)(1,088)(1,081) 
Additional paid in capital350,745321,599286,909263,941254,993112,515
Accumulated other comprehensive loss(7,558)(7,085)(9,862)(9,320)(4,150) 
Accumulated deficit(241,238)(233,316)(185,593)(152,018)(67,964) 
Other undisclosed stockholders' equity attributable to parent     (26,497)
Total stockholders' equity:100,82280,13490,403101,550181,83286,041
TOTAL LIABILITIES AND EQUITY:106,436135,192151,406147,066207,903115,536

Income statement (P&L) ($ in thousands)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues35,41225,57338,551678767123
Revenue, net25,57338,551678767123
Cost of revenue(7,800)(16,737)(3,518)(1,909)(2,337)(108)
Cost of goods and services sold(6,783)(16,387)(3,139)(365)(333)(108)
Gross profit:27,6128,83635,033(1,231)(1,570)15
Operating expenses(39,500)(53,292)(65,852)(88,265)(40,039)(19,926)
Other undisclosed operating income     48
Operating loss:(11,888)(44,456)(30,819)(89,496)(41,609)(19,863)
Nonoperating income (expense)(2,834)(3,054)(2,756)3,7441,350121
Other nonoperating income (expense)(109)(22)2555,1402,287 
Interest and debt expense(3,391)(3,481)(3,396)(1,585)(1,060)(432)
Other undisclosed income from continuing operations before equity method investments, income taxes3,3913,4813,3961,5851,060 
Loss from continuing operations before equity method investments, income taxes:(14,722)(47,510)(33,575)(85,752)(40,259)(20,174)
Other undisclosed income from continuing operations before income taxes     432
Loss from continuing operations before income taxes:(14,722)(47,510)(33,575)(85,752)(40,259)(19,742)
Income tax benefit   1,6981,44315,455
Net loss available to common stockholders, diluted:(14,722)(47,510)(33,575)(84,054)(38,816)(4,287)

Comprehensive Income ($ in thousands)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(14,722)(47,510)(33,575)(84,054)(38,816)(4,287)
Other comprehensive income (loss)(473)2,777(542)(5,170)(4,150) 
Comprehensive loss, net of tax, attributable to parent:(15,195)(44,733)(34,117)(89,224)(42,966)(4,287)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: